Target Name: WBP1L
NCBI ID: G54838
Review Report on WBP1L Target / Biomarker Content of Review Report on WBP1L Target / Biomarker
WBP1L
Other Name(s): MGC125648 | WBP1L variant 1 | WW domain binding protein 1 like | FLJ20367 | outcome predictor in acute leukemia 1 | WW domain binding protein 1-like | FLJ20154 | WW domain binding protein 1 like, transcript variant 2 | WBP1L_HUMAN | C10orf26 | OPA1L | Outcome predictor in acute leukemia 1 | OPAL1 | WW domain binding protein 1 like, transcript variant 1 | WW domain binding protein 1-like (isoform 2) | WW domain binding protein 1-like (isoform 1) | WBP1L variant 2 | Hypothetical protein LOC54838

WBP1L: A Potential Drug Target and Biomarker

WBP1L, also known as Wilms tumor 1-like gene, is a gene that has been identified in various studies as having potential to be a drug target and biomarker for various diseases, including cancer. The Wilms tumor is a type of kidney cancer that is usually born with, and can be treated with, a high risk of recurrence. Therefore, finding potential drug targets and biomarkers for Wilms tumor could have a significant impact on the treatment and management of this disease.

WBP1L is a gene that encodes a protein known as Wilms tumor 1 (WT1), which is a transcription factor that plays a role in the development and maintenance of Wilms tumors. The WT1 gene has been implicated in the development and progression of various cancers, including Wilms tumors. Therefore, it is possible that WBP1L may be a potential drug target for these cancers.

One of the key challenges in developing drug targets for cancer is the development of resistance to these treatments, which can occur as a result of genetic alterations in cancer cells. However, studies have shown that WBP1L is a promising biomarker for cancer, as it has been shown to be overexpressed in various types of cancer, including Wilms tumors. This suggests that targeting WBP1L may be a promising strategy for cancer treatment.

Another potential mechanism by which WBP1L may be involved in the development and progression of cancer is its role in cell signaling pathways. The WBP1L gene has been shown to be involved in various signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of cancer. Therefore, targeting WBP1L with drugs that can inhibit TGF-β signaling may be a promising strategy for cancer treatment.

In addition to its potential role in cancer development, WBP1L has also been shown to be involved in the regulation of stem cell properties. The stem cell is a cell that has the ability to develop into any type of cell in the body, and is a key factor in the development and treatment of many diseases, including cancer. Therefore, targeting WBP1L with drugs that can modulate stem cell properties may be a promising strategy for the treatment of cancer.

Overall, WBP1L is a gene that has shown promise as a potential drug target and biomarker for cancer. Further research is needed to fully understand its role in the development and progression of cancer, as well as its potential as a drug target. However, studies have shown that targeting WBP1L with drugs that can inhibit TGF-β signaling or modulate stem cell properties may be a promising strategy for cancer treatment.

Protein Name: WW Domain Binding Protein 1 Like

The "WBP1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WBP1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1